ADMA Biologics sees earnings estimate increase amid market decline
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 28 2026
0mins
Should l Buy ADMA?
Source: NASDAQ.COM
ADMA Biologics Inc. has experienced a significant price drop of 8.46%, hitting a 52-week low.
The company reported a 12.9% increase in its current year earnings estimate, indicating growing market demand in the treatment of immunodeficient patients, which could lead to significant revenue growth for ADMA. This positive news comes despite the broader market decline, with the Nasdaq-100 down 0.80% and the S&P 500 down 0.31%, suggesting a potential sector rotation.
This earnings estimate increase reflects ADMA's strong position in the biopharmaceutical market, which may attract investor interest despite the current market conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Responds to Negative Short Report
- Response to Negative Report: ADMA Biologics addressed the negative short report issued by Culper Research on March 24, 2026, emphasizing that the report is based on unreliable sources and contains numerous misleading and inaccurate statements, which could impact investor confidence.
- Commitment to Compliance: ADMA and its Board of Directors reaffirm their commitment to comply with U.S. Securities and Exchange Commission regulations, ensuring fair and accurate reporting of operational and financial results to maintain transparency and investor trust.
- Product Line Overview: ADMA currently manufactures and markets three FDA-approved plasma-derived biologics specifically for treating immunodeficient patients, showcasing the company's expertise and market positioning in the biopharmaceutical sector.
- R&D Progress: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumoniae, indicating the company's ongoing efforts in innovative drug development aimed at addressing the needs of specific patient populations.
See More
ADMA Biologics Inc. Initiates Review of Claims Made in Short Report
Overview of ADMA Biologics: ADMA Biologics is a company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and other related conditions.
Recent Developments: The company has been taking appropriate steps to enhance its operations and address assertions made in a recent short report, indicating a proactive approach to stakeholder concerns.
Financial Performance: ADMA Biologics has reported its financial results, showcasing growth and strategic initiatives aimed at improving its market position and product offerings.
Future Outlook: The company is optimistic about its future prospects, emphasizing ongoing research and development efforts to expand its portfolio and meet patient needs.
See More
ADMA Biologics Shares Drop 15% Amid Short Report
- Impact of Short Report: ADMA Biologics' shares fell 15% following a short report from Culper Research, indicating market concerns about the company's future performance, which could undermine investor confidence and shareholder value.
- Lack of Response: ADMA did not immediately respond to Seeking Alpha's request for comment, raising questions about the company's transparency and communication capabilities, potentially exacerbating investor unease.
- Share Repurchase Plan: ADMA announced a $125 million accelerated share repurchase agreement with JPMorgan, aiming to enhance earnings per share by reducing the float, which, despite the current stock decline, reflects the company's confidence in its intrinsic value.
- Future Revenue Forecast: ADMA forecasts $635 million in revenue for 2026, driven by ASCENIV and new supply agreements, indicating long-term growth potential despite facing short-term pressures.
See More
Adma Biologics Shares Drop After Short Report
- Stock Price Decline: Shares of Adma Biologics Inc. (ADMA) fell 6% on Tuesday following Culper Research's announcement of a short position, indicating strong investor concern regarding the company's future performance.
- Short Selling Allegations: Culper Research accused Adma's reported growth of being a “fiction,” claiming it is largely driven by a de facto channel stuffing scheme and undisclosed related party distributors, which could have long-term reputational implications for the company.
- Revenue Forecast Downgrade: Culper estimates that without channel stuffing, Adma's revenues will decline by 3% in 2025, contrasting sharply with the reported 20% growth, which may erode investor confidence in the company's future profitability.
- Market Reaction: Investors can receive updates on this developing story directly on Stocktwits, reflecting heightened market scrutiny and anxiety regarding Adma's future developments.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- Earnings Growth: Lifetime Brands (LCUT) has seen a 35.6% increase in its current year earnings estimate over the past 60 days, indicating strong growth potential in the kitchenware design and marketing sector, which could drive stock price appreciation.
- Oilfield Services Demand: Enerflex Ltd. (EFXT) has experienced a 19.5% rise in its current year earnings estimate in the last 60 days, reflecting robust demand in the natural gas and petroleum production services market, likely enhancing its competitive position.
- Automotive Supply Chain Strength: Magna International (MGA) has seen a 13.9% increase in its current year earnings estimate over the past 60 days, suggesting that its expertise in vehicle engineering and contract manufacturing will further enhance its market share.
- Biopharmaceutical Market Potential: ADMA Biologics (ADMA) has reported a 12.9% increase in its current year earnings estimate, indicating growing market demand in the treatment of immunodeficient patients, which could lead to significant revenue growth for the company.
See More
ADMA Biologics Announces $200 Million Capital Return Initiative
- Capital Return Initiative: ADMA Biologics has announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, highlighting the company's commitment to enhancing shareholder value.
- Repurchase Agreement Details: Under the ASR agreement, ADMA will pay JPMorgan an upfront amount of $125 million and is expected to initially receive about 6.4 million shares of common stock around March 3, 2026, representing approximately 80% of the anticipated repurchased shares, reflecting confidence in the current stock price.
- Progress on Buyback Program: Since the authorization of the buyback program in May 2025, ADMA has repurchased approximately $160 million of its common stock, indicating a disciplined and opportunistic approach to capital allocation aimed at enhancing long-term shareholder value.
- Future Outlook: ADMA forecasts revenue of $635 million for 2026, as ASCENIV drives margin expansion and new supply agreements extend the growth runway, positioning the company for continued success.
See More
ADMA Biologics Responds to Negative Short Report
- Response to Negative Report: ADMA Biologics addressed the negative short report issued by Culper Research on March 24, 2026, emphasizing that the report is based on unreliable sources and contains numerous misleading and inaccurate statements, which could impact investor confidence.
- Commitment to Compliance: ADMA and its Board of Directors reaffirm their commitment to comply with U.S. Securities and Exchange Commission regulations, ensuring fair and accurate reporting of operational and financial results to maintain transparency and investor trust.
- Product Line Overview: ADMA currently manufactures and markets three FDA-approved plasma-derived biologics specifically for treating immunodeficient patients, showcasing the company's expertise and market positioning in the biopharmaceutical sector.
- R&D Progress: ADMA is developing SG-001, a pre-clinical hyperimmune globulin targeting S. pneumoniae, indicating the company's ongoing efforts in innovative drug development aimed at addressing the needs of specific patient populations.
See More
ADMA Biologics Inc. Initiates Review of Claims Made in Short Report
Overview of ADMA Biologics: ADMA Biologics is a company focused on developing and commercializing specialty biologics for the treatment of immune deficiencies and other related conditions.
Recent Developments: The company has been taking appropriate steps to enhance its operations and address assertions made in a recent short report, indicating a proactive approach to stakeholder concerns.
Financial Performance: ADMA Biologics has reported its financial results, showcasing growth and strategic initiatives aimed at improving its market position and product offerings.
Future Outlook: The company is optimistic about its future prospects, emphasizing ongoing research and development efforts to expand its portfolio and meet patient needs.
See More
ADMA Biologics Shares Drop 15% Amid Short Report
- Impact of Short Report: ADMA Biologics' shares fell 15% following a short report from Culper Research, indicating market concerns about the company's future performance, which could undermine investor confidence and shareholder value.
- Lack of Response: ADMA did not immediately respond to Seeking Alpha's request for comment, raising questions about the company's transparency and communication capabilities, potentially exacerbating investor unease.
- Share Repurchase Plan: ADMA announced a $125 million accelerated share repurchase agreement with JPMorgan, aiming to enhance earnings per share by reducing the float, which, despite the current stock decline, reflects the company's confidence in its intrinsic value.
- Future Revenue Forecast: ADMA forecasts $635 million in revenue for 2026, driven by ASCENIV and new supply agreements, indicating long-term growth potential despite facing short-term pressures.
See More
Adma Biologics Shares Drop After Short Report
- Stock Price Decline: Shares of Adma Biologics Inc. (ADMA) fell 6% on Tuesday following Culper Research's announcement of a short position, indicating strong investor concern regarding the company's future performance.
- Short Selling Allegations: Culper Research accused Adma's reported growth of being a “fiction,” claiming it is largely driven by a de facto channel stuffing scheme and undisclosed related party distributors, which could have long-term reputational implications for the company.
- Revenue Forecast Downgrade: Culper estimates that without channel stuffing, Adma's revenues will decline by 3% in 2025, contrasting sharply with the reported 20% growth, which may erode investor confidence in the company's future profitability.
- Market Reaction: Investors can receive updates on this developing story directly on Stocktwits, reflecting heightened market scrutiny and anxiety regarding Adma's future developments.
See More
Five Stocks Added to Zacks Rank #1 (Strong Buy) List
- Earnings Growth: Lifetime Brands (LCUT) has seen a 35.6% increase in its current year earnings estimate over the past 60 days, indicating strong growth potential in the kitchenware design and marketing sector, which could drive stock price appreciation.
- Oilfield Services Demand: Enerflex Ltd. (EFXT) has experienced a 19.5% rise in its current year earnings estimate in the last 60 days, reflecting robust demand in the natural gas and petroleum production services market, likely enhancing its competitive position.
- Automotive Supply Chain Strength: Magna International (MGA) has seen a 13.9% increase in its current year earnings estimate over the past 60 days, suggesting that its expertise in vehicle engineering and contract manufacturing will further enhance its market share.
- Biopharmaceutical Market Potential: ADMA Biologics (ADMA) has reported a 12.9% increase in its current year earnings estimate, indicating growing market demand in the treatment of immunodeficient patients, which could lead to significant revenue growth for the company.
See More
ADMA Biologics Announces $200 Million Capital Return Initiative
- Capital Return Initiative: ADMA Biologics has announced a capital return initiative targeting approximately $200 million in 2026, including a $125 million accelerated share repurchase agreement with JPMorgan, highlighting the company's commitment to enhancing shareholder value.
- Repurchase Agreement Details: Under the ASR agreement, ADMA will pay JPMorgan an upfront amount of $125 million and is expected to initially receive about 6.4 million shares of common stock around March 3, 2026, representing approximately 80% of the anticipated repurchased shares, reflecting confidence in the current stock price.
- Progress on Buyback Program: Since the authorization of the buyback program in May 2025, ADMA has repurchased approximately $160 million of its common stock, indicating a disciplined and opportunistic approach to capital allocation aimed at enhancing long-term shareholder value.
- Future Outlook: ADMA forecasts revenue of $635 million for 2026, as ASCENIV drives margin expansion and new supply agreements extend the growth runway, positioning the company for continued success.
See More
